Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis

NCT00527267 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00527267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00527267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2002
Completion date
April 30, 2003
Enrollment
320 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hyperparathyroidism